Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML

Neurology1 Nov 2008Cited by 73 (Europe PMC)

PMID19015485DOI10.1212/01.wnl.0000335163.88054.e7PepBankPUB-19015485

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer disease, CIBIC-plus scores did not differ significantly between MK‑677 and placebo.
In plain wordsIn patients with Alzheimer disease, CIBIC-plus scores did not differ significantly between MK‑677 and placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCIBIC-plus
Study
n = 416
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
25 mg daily · 12 monthsAs given in this study (human).
Source sentences
Summary
there were no significant differences between the treatment groups on the CIBIC-plus or the mean change from baseline scores on the ADAS-Cog, ADCS-ADL, or CDR-sob scores over 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months.
Report a problemFND-1901548503
02HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer disease, ADAS-Cog changes did not differ significantly between MK‑677 and placebo.
In plain wordsIn patients with Alzheimer disease, ADAS-Cog changes did not differ significantly between MK‑677 and placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeADAS-Cog
Study
n = 416
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
25 mg daily · 12 monthsAs given in this study (human).
Source sentences
Summary
there were no significant differences between the treatment groups on the CIBIC-plus or the mean change from baseline scores on the ADAS-Cog, ADCS-ADL, or CDR-sob scores over 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months.
Report a problemFND-1901548504
03HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer disease, ADCS-ADL changes did not differ significantly between MK‑677 and placebo.
In plain wordsIn patients with Alzheimer disease, daily activity score changes did not differ significantly between MK‑677 and placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeADCS-ADL
Study
n = 416
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
25 mg daily · 12 monthsAs given in this study (human).
Source sentences
Summary
there were no significant differences between the treatment groups on the CIBIC-plus or the mean change from baseline scores on the ADAS-Cog, ADCS-ADL, or CDR-sob scores over 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months.
Report a problemFND-1901548505
04HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer disease, CDR-sob changes did not differ significantly between MK‑677 and placebo.
In plain wordsIn patients with Alzheimer disease, CDR-sob changes did not differ significantly between MK‑677 and placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCDR-sob
Study
n = 416
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
25 mg daily · 12 monthsAs given in this study (human).
Source sentences
Summary
there were no significant differences between the treatment groups on the CIBIC-plus or the mean change from baseline scores on the ADAS-Cog, ADCS-ADL, or CDR-sob scores over 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months.
Report a problemFND-1901548506
05HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer disease, MK‑677 increased serum IGF-1 by 60.1% at 6 weeks.
In plain wordsIn patients with Alzheimer disease, MK‑677 25 mg was followed by a 60.1% rise in IGF-1 at 6 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-1 at 6 weeks
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · 6 weeksAs given in this study (human).
Measurements
Serum IGF-1 increase
60.1%
MK-677 25 mg, week 6
Source sentences
Summary
Administration of MK-677 25 mg resulted in a 60.1% increase in serum IGF-1 levels at 6 weeks and a 72.9% increase at 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months.
Report a problemFND-1901548501
06HumanRandomized controlled trialEfficacy outcome
In patients with Alzheimer disease, MK‑677 increased serum IGF-1 by 72.9% at 12 months.
In plain wordsIn patients with Alzheimer disease, MK‑677 25 mg was followed by a 72.9% rise in IGF-1 at 12 months.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-1 at 12 months
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · 12 monthsAs given in this study (human).
Measurements
Serum IGF-1 increase
72.9%
MK-677 25 mg, month 12
Source sentences
Summary
Administration of MK-677 25 mg resulted in a 60.1% increase in serum IGF-1 levels at 6 weeks and a 72.9% increase at 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months.
Report a problemFND-1901548502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00074529

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Merck Sharp & Dohme LLCn = 512Oct 2003 to Jan 2006

Alzheimer's Disease

Trial page ClinicalTrials.govUpdated 24 Jul 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.